Institut Sainte Catherine

Recent papers from Institut Sainte Catherine

1. Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trialThe Lancet · 2025
2. Efficacy and safety of pembrolizumab–lenvatinib in metastatic endometrial cancer: results from the French multicenter early access programESMO Open · 2026
3. Continuous Intravenous Lidocaine for Refractory Cancer Pain in Palliative Care: A Multicenter Feasibility StudyJournal of Palliative Care · 2026
4. Predicting severe toxicities and mortality in older patients with colorectal cancer: An analysis of 3 clinical trials and 3 prospective cohorts.European Journal of Cancer · 2026
5. Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trialTranslational Oncology · 2026
6. Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD study2026
7. Strengthening incident learning in radiotherapy practice: insights from the MARLIN studyClinical and Translational Radiation Oncology · 2026
8. Amivantamab in recurrent/metastatic HNSCC after checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 studyJournal of Clinical Oncology · 2026
9. TUC-TOC phase II trial (NCT05955170): Tucatinib in combination with oral etoposide (VP16) and trastuzumab in patients with metastatic HER2-positive breast cancer (HER2+ mBC).Journal of Clinical Oncology · 2026
10. IFCT-2401 SPORADIC trial: Integrating cemiplimab to sequential hypofractionated chemoradiotherapy for unfit or elderly patients with unresectable stage III non–small cell lung cancer.Journal of Clinical Oncology · 2026
11. Amivantamab in HPV-unrelated recurrent/metastatic head and neck squamous cell cancer after disease progression on immune checkpoint inhibitor and chemotherapy: Pivotal results from the phase 1b/2 OrigAMI-4 study.Journal of Clinical Oncology · 2026
12. 68P Clinical value of Circulating Tumor Cells (CTC) in the phase III randomized AMBRE trial comparing chemotherapy (CT) vs endocrine therapy (ET) and Abemaciclib in HR+HER2- advanced breast cancer (ABC)ESMO Open · 2026
13. 527P Title results of the safety run-in part of the TUC-TOC phase II trial (NCT05955170): Tucatinib in combination with oral etoposide (VP16) - trastuzumab in patients with metastatic HER2-positive breast cancer (HER2+ mBC)ESMO Open · 2026
14. 273P Long-term efficacy of adjuvant abemaciclib + endocrine therapy (ET) in key subgroups in the monarchE trialESMO Open · 2026
15. Abstract CT275: ALTER: A randomized Phase II trial evaluating an upfront alternating regimen of sacituzumab-govitecan and trastuzumab-deruxtecan versus sacituzumab-govitecan alone in HER2-low metastatic triple-negative breast cancer (NCT07151586)Cancer Research · 2026
16. Durvalumab combined with weekly carboplatin/paclitaxel as first-line treatment of patients with recurrent and/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNEESMO Open · 2026
17. Abstract PS2-02-09: Fr-pop: Real-world data from 7,687 high-risk TNBC patients treated with perioperative pembrolizumab in FranceClinical Cancer Research · 2026
18. Abstract PS1-01-04: Efficacy of cryotherapy using frozen gloves and socks to prevent docetaxel-induced onycholysis in early breast cancer patients undergoing sequential (neo)adjuvant (F)EC and docetaxel treatment: The Banquise randomized controlled trialClinical Cancer Research · 2026
19. Abstract PS3-09-11: Acceptability of adjuvant chemotherapy in women aged 70 and older after surgery for ER-positive HER2-negative breast cancer selected with a high genomic grade index: results from the ASTER 70s/Unicancer trialClinical Cancer Research · 2026
20. Abstract RF7-06: Primary results of Ambre, a randomized phase 3comparing mono-chemotherapy (ct) vs abemaciclib + endocrine therapy (et) in hr+/her2- advanced breast cancer (abc) with high visceral tumor burdenClinical Cancer Research · 2026